Overview

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Status:
RECRUITING
Trial end date:
2026-03-18
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Affiliated Hospital of Nantong University
Collaborator:
Shanghai First Song Biotechnology Co., LTD
Treatments:
Cyclophosphamide
fludarabine